Innovative Non-Invasive Testing MiRNA Scientific offers the proprietary miR Sentinel™ Prostate Cancer Test, a groundbreaking non-invasive liquid biopsy urine test that accurately detects and monitors prostate cancer, presenting a strong opportunity to target urological cancer clinics and urology specialists seeking advanced diagnostic solutions.

Growth in Precision Healthcare As a company focused on transforming cancer management through its proprietary platform, MiRNA Scientific positions itself well to collaborate with hospitals, research institutions, and healthcare providers aiming to adopt value-based, molecular-level cancer diagnostics.

Market Expansion Potential With revenues between $10M and $25M and a focus on molecular diagnostics, MiRNA Scientific is poised for growth alongside larger players in the biotechnology and cancer diagnostics sectors, creating opportunities for strategic partnerships and expanding distribution channels.

Technology-Driven Approach Utilizing advanced digital tools such as Google Analytics and Insightly CRM, MiRNA Scientific demonstrates a sophisticated approach to market engagement and customer management, which can be leveraged to enhance outreach to healthcare providers and research organizations.

Emerging Industry Player As a smaller but innovative biotech firm competing in a space with established companies like Guardant Health and Myriad Genetics, MiRNA Scientific offers potential for strategic alliances or acquisition interest from larger firms looking to expand their precision oncology portfolios.